Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Pompano Beach, FL, Feb. 16, 2018 -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today that it has completed its application to uplist on OTCQX, a higher tier Over The Counter (OTC) market overseen by OTCMarkets, Inc.
OTCQX is a segment of the OTC marketplace reserved for publicly traded companies that have: (a) attained specific quantitative and qualitative financial standards; (b) passed management reviews; (c) issued timely information to the public; (d) remained current on required disclosures, and (e) consistently shared pertinent updates with investors. OTCQX companies are more widely quoted across the electronic and retail brokerage markets.
Henry Van Vurst, CEO of BioStem Technologies, stated, "We’ve been aggressively preparing for this uplist for months now, meeting all financial reporting obligations and completing the submission of all application documents required by OTCMarkets, Inc. We expect the uplist to add value for our shareholders by enabling our stock to be quoted and traded by a much wider range of brokerages, particularly retail brokers.”
The stocks of approximately 10,000 companies are traded daily in the multi-tiered OTC Markets, but only companies in the top tier qualify to trade on the OTCQX. Those companies are characterized by operational excellence and consistent reporting diligence. “BSEM is certainly qualified for that top tier, and we expect our application to be quickly approved,” added Mr. Van Vurst.
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc. is a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine. The Company’s mission is to discover, develop and produce the most effective Pharmaceutical and Regenerative Medicine products in the world. The Company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.
BioStem Technologies, Inc. Phone: 954-380-8342 Website: http://www.biostemtech.com Email: [email protected] Twitter: @Biostemtech Facebook: BioStem Technologies Investor Relations: Andrew Van Vurst [email protected] (954) 380-8342
